Abstract
Phospholipid ethers (PLE) provide an innovative approach to preferentially target cancer cells by capitalizing on their increased number/size of lipid rafts. PLE are designed to possess high affinity to lipid rafts which upon binding results in internalization and the ability to deliver an attached warhead to the cytosol. CLR 131 is a novel PLE conjugated to I-131, which was chosen due to its 8-day half-life and well-established efficacy in multiple cancer types. Preclinical/phase I data has shown CLR 131 to be preferentially taken up by cancer cells and to cross the blood brain barrier.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call